ENTERPRISE AI ANALYSIS
High-throughput ligand diversification to discover chemical inducers of proximity
This study introduces a groundbreaking high-throughput ligand diversification strategy, based on sulfur(VI) fluoride exchange (SuFEx) chemistry, for the prospective discovery of chemical inducers of proximity (CIPs). By systematically modifying existing protein ligands, researchers successfully identified novel molecular glues. Key findings include dHTC1, an ENL degrader that cooperatively recruits CRL4CRBN through an ENL-dependent mechanism, and dHTC3, a molecular glue that selectively dimerizes BRD4 bromodomain 1 with the previously inaccessible E3 ligase SCFFBX03. This innovation accelerates the discovery of molecular glues, opening new avenues for proximity pharmacology and targeting difficult-to-drug proteins with enhanced selectivity and favorable in vivo properties.
Executive Impact: Accelerating Drug Discovery with Novel CIPs
Our AI-driven analysis quantifies the immediate benefits for your R&D pipeline.
Novel CIPs Discovered
Ligands Diversified via HTC
dHTC1 Cooperativity Increase
Novel E3 Ligase Unlocked
Deep Analysis & Enterprise Applications
Select a topic to dive deeper, then explore the specific findings from the research, rebuilt as interactive, enterprise-focused modules.
Pioneering New Approaches in Proximity Pharmacology
This research unveils novel Chemical Inducers of Proximity (CIPs) and elucidates their unique mechanisms of action, setting new benchmarks for molecular glue discovery. The findings highlight how high-throughput chemistry can yield compounds with unprecedented target specificity and E3 ligase engagement, addressing critical challenges in current drug development. Understanding these nuanced interactions paves the way for designing next-generation therapeutics that can precisely modulate biological pathways.
High-Throughput Chemistry: A Paradigm Shift
The core innovation lies in the systematic application of high-throughput chemistry (HTC), specifically SuFEx-based diversification, to transform existing ligands into powerful CIPs. This approach moves beyond serendipitous discoveries, offering a prospective and scalable method for identifying molecular glues. The integration of HTC with miniaturized cellular screens provides a rapid feedback loop for lead optimization, significantly de-risking early-stage drug discovery efforts and expanding the chemical space for proximity-inducing molecules.
Enterprise Process Flow: HTC for CIP Discovery
Preexisting Ligands (ENL/BRD4)
→
SuFEx High-Throughput Chemistry
→
Install Diverse Building Blocks (3,163 Amines)
→
Cellular Degradation Screens (HiBiT-ENL/BRD4)
→
Hit Resynthesis & Validation
→
Discovery of Novel CIPs (dHTC1, dHTC3)
220-fold
Increased Cooperativity in CRBN Engagement by dHTC1 with ENL
| Feature | dHTC1 (Novel Molecular Glue) | SR-1114 (CRBN-based PROTAC) |
|---|---|---|
| CRBN Engagement |
|
|
| Stereoselectivity |
|
|
| E3 Ligase Interface |
|
|
| Neosubstrate Degradation |
|
|
| In Vivo Properties |
|
|
FBXO3
Novel E3 Ligase Effector Discovered for BRD4 Degradation
Case Study: dHTC3 – A BD1-Specific BRD4 Molecular Glue
The discovery of dHTC3 represents a significant leap, identifying a molecular glue that selectively targets BRD4's Bromodomain 1 (BD1) and recruits the novel E3 ligase SCFFBX03. This opens up a previously inaccessible pathway for chemical rewiring of BRD4. Through rigorous CRISPR screens and splitHaloTag assays, we confirmed that dHTC3's activity is FBXO3-dependent and exclusively mediated via BD1, as iBET-BD1 blocked its effect while iBET-BD2 did not. This specificity, coupled with the absence of a hook effect, suggests a cooperative, glue-like mechanism of action for dHTC3, demonstrating HTC's power to uncover new ligase effectors and precise targeting strategies for challenging protein families like BET bromodomains.
Calculate Your Potential ROI
See how integrating AI-driven insights and high-throughput discovery platforms can transform your R&D efficiency and financial returns.
Projected Annual Savings
$0
Annual Hours Reclaimed
0
Your AI-Powered Drug Discovery Roadmap
A structured approach to integrating cutting-edge AI and HTS methodologies into your research.
Phase 1: Assessment & Strategy (1-2 Weeks)
In-depth analysis of current R&D processes, target portfolio, and HTS infrastructure. Define specific goals for CIP discovery and molecular glue development, identifying optimal starting ligands and E3 ligases. Roadmap development for AI-integration and HTC implementation.
Phase 2: Platform Integration & Training (3-4 Weeks)
Set up SuFEx-based HTC workflows and establish miniaturized cellular screening assays. Onboard your team with training on new chemical synthesis protocols, data analysis, and AI-driven hit prioritization strategies. Initial small-scale ligand diversification pilot runs.
Phase 3: High-Throughput Discovery Cycle (6-12 Weeks)
Execute large-scale ligand diversification campaigns (e.g., 3,000+ analogs). Conduct rapid cellular screens for proximity-inducing activity. Leverage AI for rapid hit identification, structural analysis, and prediction of cooperativity and specificity, accelerating lead identification.
Phase 4: Mechanistic Validation & Optimization (Ongoing)
Validate novel CIPs through cryo-EM, SPR, and proteomics. Refine lead structures for improved potency, selectivity, and pharmacokinetic properties. Continuously integrate new data into AI models for iterative design and faster optimization cycles, building a robust pipeline for future discoveries.
Ready to Revolutionize Your R&D?
Connect with our experts to discuss how AI and high-throughput chemistry can accelerate your drug discovery efforts and unlock novel therapeutic opportunities.
Ready to Get Started?
Book Your Free Consultation.
Let's Discuss Your AI Strategy!
Lets Discuss Your Needs
Select a Date
Sun
Mon
Tue
Wed
Thu
Fri
Sat